摘要
目的探讨髓细胞白血病基因-1（MCL-1）在胆管癌组织中的表达及对预后的意义。方法采用免疫组织化学技术检测MCL-1在70例胆管癌组织和15例非肿瘤胆道上皮组织中的表达。结果免疫组织化学结果显示70例胆管癌、15例非肿瘤胆道上皮组织中MCL-1阳性表达率分别为72.9%、26.7%。MCL-1蛋白在胆管癌中的表达明显高于非肿瘤胆道上皮组织（χ2＝11.541，P＝0.001）。MCL-1蛋白表达与胆管癌的临床分期、淋巴结转移和组织学分级明显相关（χ2＝4.048，P＝0.044；χ2＝6.369，P＝0.012；χ2＝6.466，P＝0.039）。MCL-1蛋白阴性表达组生存时间明显长于阳性表达组（χ2＝5.980，P＝0.015）。结论检测MCL-1有助于反映胆管癌发生发展及预后。
Objective To investigate the expression of myeloid cell leukemia sequence-1 （MCL-1） in cholangiocarcinoma tissues and its clinical significance to prognosis.MethodsImmunohistochemical staining was used to detect the expression of MCL-1 in 70 cases of cholangiocarcinoma and 15 cases of non-tumor bile duct epithelium.ResultsThe expression rates of MCL-1 in cholangiocarcinoma （72.9%） were significantly higher than those in non-tumor bile duct epithelium （26.7%; χ2=11.541, P=0.001）. MCL-1 expression rates significantly correlated with clinical stage, lymph nodes metastasis and tumor grade. The positive rates of MCL-1 were significantly higher in the stage Ⅲ＋ Ⅳ, lymph nodes metastasis and moderately or poorly-differentiated group than those in stageⅠ＋ Ⅱ group, no lymph nodes metastasis and well-differentiated group （χ2=4.048, P=0.044; χ2=6.369, P=0.012; χ2=6.466, P=0.039）. The survival time of negative expression of MCL-1 group were significantly longer than those of positive expression of MCL-1 group （χ2=5.980, P=0.015）.ConclusionMCL-1 may be an important biomarker in carcinogenesis, progression and prognosis of cholangiocarcinoma.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2018年第1期133-135,共3页
Chinese Journal of Experimental Surgery
关键词
胆管癌
髓细胞白血病基因-1
预后
Cholangiocarcinoma
Myeloid cell leukemia sequence-1
Prognosis
